Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An announcement from Barinthus Biotherapeutics ( (BRNS) ) is now available.
Barinthus Biotherapeutics has announced the promotion of Geoffrey Lynn, M.D., Ph.D., as the new Chief Scientific Officer, succeeding Nadège Pelletier, Ph.D. This leadership change comes as the company advances its innovative immunotherapeutic pipeline, including promising treatments for chronic hepatitis B and celiac disease. Investors in the biotech sector can look forward to Dr. Lynn’s expertise in driving the development of cutting-edge therapies that aim to tackle autoimmune diseases and chronic infections.
Find detailed analytics on BRNS stock on TipRanks’ Stock Analysis page.
